- Home
- TSHA vs NEO Comparison
TSHA vs NEO Comparison
Compare TSHA & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | NEO |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | TSHA | NEO |
|---|---|---|
| Price | $4.49 | $12.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $10.56 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 02-25-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,310,000.00 | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.86 |
| Revenue Next Year | N/A | $9.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $1.05 | $4.72 |
| 52 Week High | $6.02 | $15.32 |
Technical Indicators
Market Signals| Indicator | TSHA | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 47.20 |
| Support Level | $4.50 | $12.04 |
| Resistance Level | $4.89 | $13.29 |
| Average True Range (ATR) | 0.31 | 0.64 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 12.06 | 17.68 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.